HYPMY: AI 评分 45/100 — AI 分析 (4月 2026)

Hypera S.A. is a leading Brazilian pharmaceutical company with a diverse portfolio of branded prescription, consumer health, and generic products. The company leverages its strong brand recognition and distribution network to maintain a significant market share in the Brazilian pharmaceutical market.

Key Facts: AI Score: 45/100 Sector: Healthcare

公司概况

概要：

Hypera S.A., based in Brazil, is a pharmaceutical company focused on branded prescription drugs, consumer health products, and generics. With a diverse portfolio including well-known brands like Benegrip and Addera, Hypera leverages its established distribution network and brand recognition to maintain a strong presence in the competitive Brazilian pharmaceutical market, demonstrating a P/E ratio of 11.78 and a dividend yield of 5.30%.

HYPMY是做什么的？

Hypera S.A., formerly known as Hypermarcas S.A., was founded with the vision of becoming a leading pharmaceutical company in Brazil. The company has evolved through strategic acquisitions and organic growth, building a comprehensive portfolio of pharmaceutical products. Hypera operates in three primary segments: branded prescription drugs, consumer health products, and similar and generic medicines. Its branded prescription portfolio includes products like Adacne, Addera, and Celestamine, addressing various therapeutic areas. The consumer health segment features well-known brands such as Benegrip, Engov, and Epocler, catering to over-the-counter healthcare needs. Additionally, Hypera offers a range of generic medicines under the Neo Química brand, providing affordable treatment options. Hypera's dermo-cosmetics segment operates under the Mantecorp Skincare brand. The company has a strong distribution network across Brazil, ensuring its products are readily available to consumers. Hypera S.A. changed its name in February 2018 and is headquartered in São Paulo, Brazil, employing over 10,481 individuals.

HYPMY的投资论点是什么？

Hypera S.A. presents a notable market position due to its strong market position in the Brazilian pharmaceutical industry and diversified product portfolio. With a P/E ratio of 11.78 and a dividend yield of 5.30%, the company demonstrates financial stability and potential for shareholder returns. Key value drivers include the continued growth of its branded prescription and consumer health segments, expansion into new therapeutic areas, and strategic acquisitions. The company's established distribution network and brand recognition provide a competitive advantage. However, potential may be worth researching risks such as regulatory changes, currency fluctuations, and competition from other pharmaceutical companies. The company's beta of 0.20 indicates low volatility compared to the overall market.

HYPMY在哪个行业运营？

Hypera S.A. operates within the Brazilian pharmaceutical industry, which is characterized by increasing demand for healthcare products and services. The market is driven by an aging population, rising disposable incomes, and growing awareness of health and wellness. The competitive landscape includes both domestic and international pharmaceutical companies. Hypera competes with companies like APNHF (Apotex Inc.), APNHY (Apotex Corp), BVNKF (Bayer AG), BVNRY (Bayer Corp), and DMPHF (Daiichi Sankyo), each vying for market share across various therapeutic areas. The industry is subject to regulatory oversight and pricing pressures, impacting profitability and growth strategies.

Drug Manufacturers - Specialty & Generic

Healthcare

HYPMY有哪些增长机遇？

Expansion of Branded Prescription Portfolio: Hypera can drive growth by expanding its portfolio of branded prescription drugs through strategic acquisitions and in-licensing agreements. Focusing on high-growth therapeutic areas such as cardiology, dermatology, and neurology can increase revenue and market share. The Brazilian prescription drug market is projected to reach $30 billion by 2028, offering substantial growth potential for Hypera.
Strengthening Consumer Health Segment: Hypera can further strengthen its consumer health segment by introducing innovative over-the-counter products and expanding its distribution network. Focusing on categories such as pain relief, cough and cold, and vitamins and supplements can drive revenue growth. The Brazilian consumer health market is estimated at $15 billion, providing ample opportunity for Hypera to increase its market presence.
Geographic Expansion within Brazil: Hypera can expand its geographic reach within Brazil by targeting underserved regions and increasing its presence in key metropolitan areas. Investing in sales and marketing initiatives to promote its products in these regions can drive revenue growth. Brazil's diverse geographic landscape offers significant potential for Hypera to tap into new markets and customer segments.
Leveraging Digital Channels: Hypera can leverage digital channels to enhance its marketing efforts and improve customer engagement. Investing in e-commerce platforms, social media marketing, and online advertising can drive brand awareness and increase sales. The growing adoption of digital technologies in Brazil presents a significant opportunity for Hypera to reach a wider audience and improve its customer experience.
Strategic Partnerships and Collaborations: Hypera can pursue strategic partnerships and collaborations with other pharmaceutical companies, research institutions, and healthcare providers to expand its product portfolio and access new technologies. Collaborating with international companies can provide access to innovative products and markets. These partnerships can accelerate Hypera's growth and enhance its competitive position in the Brazilian pharmaceutical market.

Market capitalization of $2.68 billion, reflecting its significant presence in the Brazilian pharmaceutical market.
P/E ratio of 11.78, indicating a potentially undervalued stock compared to its earnings.
Profit margin of 15.5%, demonstrating efficient operations and profitability.
Gross margin of 57.7%, showcasing strong pricing power and cost management.
Dividend yield of 5.30%, offering an attractive income stream for investors.

HYPMY提供哪些产品和服务？

Develops, manufactures, and markets a wide range of pharmaceutical products.
Offers branded prescription drugs for various therapeutic areas.
Provides over-the-counter consumer health products.
Manufactures and distributes generic medicines.
Offers dermo-cosmetic products under the Mantecorp Skincare brand.
Provides nutritional and vitamin supplement products.

HYPMY如何赚钱？

Develops and acquires pharmaceutical products.
Manufactures products in its own facilities and through contract manufacturers.
Distributes products through a network of pharmacies and retailers.
Markets products through sales representatives and advertising campaigns.

Pharmacies and drugstores throughout Brazil.
Hospitals and clinics.
Individual consumers seeking prescription and over-the-counter medications.
Healthcare providers who prescribe and recommend Hypera's products.

Strong brand recognition for key products like Benegrip and Addera.
Extensive distribution network across Brazil.
Diversified product portfolio across multiple therapeutic areas.
Established relationships with pharmacies and healthcare providers.

什么因素可能推动HYPMY股价上涨？

Ongoing: Expansion of product portfolio through strategic acquisitions and licensing agreements.
Ongoing: Growth in the consumer health segment driven by innovative product launches.
Ongoing: Geographic expansion within Brazil targeting underserved regions.
Upcoming: Potential regulatory changes in the Brazilian pharmaceutical market that could benefit Hypera.
Upcoming: Launch of new dermo-cosmetic products under the Mantecorp Skincare brand in Q3 2026.

HYPMY的主要风险是什么？

Ongoing: Exposure to currency fluctuations between the U.S. dollar and the Brazilian real.
Ongoing: Competition from larger multinational pharmaceutical companies.
Potential: Changes in government regulations and healthcare policies in Brazil.
Potential: Patent expirations and loss of exclusivity on key products.
Potential: Economic downturn in Brazil impacting consumer spending on healthcare products.

HYPMY的核心优势是什么？

Diversified product portfolio across multiple segments.
Strong brand recognition and customer loyalty.
Extensive distribution network throughout Brazil.
Experienced management team.

HYPMY的劣势是什么？

Dependence on the Brazilian market.
Exposure to currency fluctuations.
Competition from larger multinational pharmaceutical companies.
Regulatory risks and pricing pressures.

HYPMY有哪些机遇？

Expansion into new therapeutic areas.
Strategic acquisitions and partnerships.
Growth in the consumer health segment.
Leveraging digital channels for marketing and sales.

HYPMY面临哪些威胁？

Increased competition from generic drug manufacturers.
Changes in government regulations and healthcare policies.
Economic downturn in Brazil.
Patent expirations and loss of exclusivity.

HYPMY的竞争对手是谁？

Apotex Inc. — Global generic pharmaceutical company. — (APNHF)
Apotex Corp — North American arm of Apotex Inc. — (APNHY)
Bayer AG — Multinational pharmaceutical and life sciences company. — (BVNKF)
Bayer Corp — US subsidiary of Bayer AG. — (BVNRY)
Daiichi Sankyo — Japanese pharmaceutical company. — (DMPHF)

Key Metrics

MoonshotScore: 45/100

Company Profile

CEO: Breno Toledo Pires de Oliveira
Headquarters: São Paulo, BR
Employees: 10,481
Founded: 2010

AI Insight

AI analysis pending for HYPMY

ADR Level: 1
ADR Ratio: 1:1
Home Market Ticker: HYPM

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Hypera S.A. do?

Hypera S.A. is a leading Brazilian pharmaceutical company that develops, manufactures, and markets a diverse range of pharmaceutical products. Its portfolio includes branded prescription drugs, over-the-counter consumer health products, generic medicines, and dermo-cosmetic products. The company operates primarily in Brazil, distributing its products through a network of pharmacies, hospitals, and retailers. Hypera focuses on providing affordable and accessible healthcare solutions to meet the needs of the Brazilian population.

What do analysts say about HYPMY stock?

Analyst coverage of HYPMY is limited due to its OTC listing and ADR Level 1 status. However, analysts generally view Hypera S.A. favorably due to its strong market position in Brazil, diversified product portfolio, and attractive dividend yield. Key valuation metrics include its P/E ratio of 11.78 and profit margin of 15.5%. Growth considerations include the company's expansion strategy, new product launches, and potential regulatory changes in the Brazilian pharmaceutical market. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks.

What are the main risks for HYPMY?

The main risks for HYPMY include exposure to currency fluctuations between the U.S. dollar and the Brazilian real, competition from larger multinational pharmaceutical companies, and potential changes in government regulations and healthcare policies in Brazil. Additionally, patent expirations and loss of exclusivity on key products could impact revenue and profitability. Economic conditions in Brazil could also affect consumer spending on healthcare products. As an OTC-listed stock, HYPMY is subject to additional risks related to liquidity, transparency, and regulatory oversight.